Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration.
Publication
, Journal Article
Riedel, RF
Published in: Lancet Oncol
January 2019
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Lancet Oncol
DOI
EISSN
1474-5488
Publication Date
January 2019
Volume
20
Issue
1
Start / End Page
14 / 15
Location
England
Related Subject Headings
- Sulfonamides
- Solitary Fibrous Tumors
- Pyrimidines
- Oncology & Carcinogenesis
- Indazoles
- Immunotherapy
- Humans
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Riedel, R. F. (2019). Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration. Lancet Oncol, 20(1), 14–15. https://doi.org/10.1016/S1470-2045(18)30745-9
Riedel, Richard F. “Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration.” Lancet Oncol 20, no. 1 (January 2019): 14–15. https://doi.org/10.1016/S1470-2045(18)30745-9.
Riedel RF. Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration. Lancet Oncol. 2019 Jan;20(1):14–5.
Riedel, Richard F. “Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration.” Lancet Oncol, vol. 20, no. 1, Jan. 2019, pp. 14–15. Pubmed, doi:10.1016/S1470-2045(18)30745-9.
Riedel RF. Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration. Lancet Oncol. 2019 Jan;20(1):14–15.
Published In
Lancet Oncol
DOI
EISSN
1474-5488
Publication Date
January 2019
Volume
20
Issue
1
Start / End Page
14 / 15
Location
England
Related Subject Headings
- Sulfonamides
- Solitary Fibrous Tumors
- Pyrimidines
- Oncology & Carcinogenesis
- Indazoles
- Immunotherapy
- Humans
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis